GEMoaB

GEMoaB GmbH is a privately held clinical-stage biopharmaceutical company headquartered in Dresden, Germany, committed to becoming a leading, fully integrated biopharmaceutical company. By focusing on our proprietary next-generation UniCAR, RevCAR, and TCE platforms, we aim to discover, develop, manufacture, and commercialize next-generation immunotherapies for the treatment of cancer patients with high unmet medical needs.Founded in 2011 by accomplished and visionary scientists, GEMoaB has rapidly grown into an ambitious R&D organization with unique proprietary immunotherapy platforms and a robust preclinical and clinical pipeline.Manufacturing represents a key bottleneck for many companies developing cellular immunotherapies for cancer patients. GEMoaB has established a preferred partnership with our sister company Cellex, located in Cologne, a world leader in manufacturing hematopoietic stem cell products and a leading CAR-T cell CMO in Europe.